Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GrifolsGRFS -2.50%83 EV-to-EBITDA is 9.50 as of Jul. 15, 2026, which is 39% below its 10-year median of 15.62. GuruFocus rates GRFS with a GF Score™ of 83/100 and a GF Value™ of $8.72 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 740 Drug Manufacturers companies, Grifols ranks better than 60.81% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Grifols's enterprise value is $17,653 Mil.
Grifols's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1,857 Mil. Therefore, Grifols's EV-to-EBITDA for today is 9.50.
The historical rank and industry rank for Grifols's EV-to-EBITDA or its related term are showing as below:
GRFS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.69 Med: 15.62 Max: 27.03
Current: 10.42
During the past 13 years, the highest EV-to-EBITDA of Grifols was 27.03. The lowest was 3.69. And the median was 15.62.
GRFS's EV-to-EBITDA is ranked better than 60.81% of 740
companies
in the Drug Manufacturers industry
Industry Median: 13.025
vs GRFS: 10.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Grifols (NAS:GRFS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grifols's share price for today is $7.02.
Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.708.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Grifols's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Grifols's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Grifols's EV-to-EBITDA falls into.
Grifols's current Enterprise Value is $17,653 Mil.
Grifols's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,857 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (GRFS) has a EV-to-EBITDA of 9.50 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Grifols. This is 39% below median its historical median of 15.62. Over the past decade, Grifols' EV-to-EBITDA has ranged from 3.69 to 27.03. According to the industry distribution chart, Grifols ranks #290 out of 740 companies in the Drug Manufacturers industry, placing it in the top 39.2%.
Is Grifols' EV-to-EBITDA too high?
Grifols' current EV-to-EBITDA of 9.50 is 39% below median its 10-year median of 15.62. Over the past 10 years, this metric has ranged from a low of 3.69 to a high of 27.03. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Grifols' value of 9.50 is 27.1% below this industry median. Based on the distribution chart, Grifols ranks #290 out of 740 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #290 out of 740 companies for EV-to-EBITDA. This puts Grifols in the upper half of its industry. The industry median EV-to-EBITDA is 13.03. Grifols' value of 9.50 is 27.1% below this benchmark. Historically, Grifols' own EV-to-EBITDA has ranged from 3.69 to 27.03 over the past decade. While the company's 10-year median is 15.62 vs. the industry median of 13.03, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current EV-to-EBITDA of 9.50 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Grifols. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current EV-to-EBITDA is 9.50, which is 39% below median its own 10-year median of 15.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.72, compared to a current price of $7.02 — trading 19.5% below its estimated fair value. The current EV-to-EBITDA is 9.50, which is 39% below median its 10-year median of 15.62 and 27.1% below the Drug Manufacturers industry median of 13.03. Grifols' overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Grifols (GRFS), the current EV-to-EBITDA is 9.50 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.02 is trading 19.5% below its estimated GF Value™ of $8.72.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
EV-to-EBITDA: 9.50 (39% below median its 10-year median of 15.62)
GF Value™: $8.72 vs. price of $7.02 (19.5% below fair value)
Industry Position: 27.1% below the Drug Manufacturers median (#290 of 740)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
83GF Score
Get the complete analysis for GRFS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
